Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463214 | 1.00 | GAA (0.50) | GAAMAPTJAK2LMNAKMT2A | |
| Bromide SCHEMBL5764896 | 0.98 | GAA (0.48) | GAAMAPTJAK2LMNAKMT2A | |
| SCHEMBL25364751 | 0.86 | PARP1 (0.50) | GAAMAPTJAK2KMT2APOLB | |
| SCHEMBL7029967 | 0.85 | KMT2A (0.52) | MAPTLMNAKMT2APOLBTSHR | |
| SCHEMBL29728552 | 0.85 | KMT2A (0.52) | MAPTLMNAKMT2APOLBTSHR | |
| SCHEMBL20573424 | 0.84 | FABP7 (0.51) | GAAMAPTJAK2LMNAKMT2A | |
| SCHEMBL30615207 | 0.84 | FABP7 (0.51) | GAAMAPTJAK2LMNAKMT2A | |
| SCHEMBL5683898 | 0.81 | GAA (0.54) | GAAMAPTJAK2LMNAKMT2A | |
| SCHEMBL20502499 | 0.79 | ESR1 (0.62) | GAAMAPTJAK2LMNAKMT2A | |
| SCHEMBL29728528 | 0.79 | KMT2A (0.46) | MAPTLMNAKMT2APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796229-B2 | Feedback prodrug | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-08-05 | — | — | US | claimed |
| WO-2010079409-A2 | USE OF AMINOCARBOXYLATE FUNCTIONALIZED CATECHOLS FOR CLEANING APPLICATIONS | ECOLAB INC. (US) | 2010-07-15 | — | — | WO | claimed |
| EP-2197921-A1 | METHOD OF MAKING CARBAMATE FUNCTIONAL MATERIALS | BASF Coatings GmbH (US) | 2010-06-23 | — | — | EP | claimed |
| US-7645731-B1 | Use of aminocarboxylate functionalized catechols for cleaning applications | ECOLAB INC. (US) | 2010-01-12 | — | — | US | claimed |
| WO-2009035667-A1 | METHOD OF MAKING CARBAMATE FUNCTIONAL MATERIALS | BASF CORPORATION (US) | 2009-03-19 | — | — | WO | claimed |
| EP-0309843-B1 | 0-(0-ETHYL-S-ALKYLPHOSPHORYL)-0-(CARBAMOYL)-PYROCATECHOL DERIVATIVES | BASF Aktiengesellschaft (DE) | 1992-01-29 | — | — | EP | claimed |
| JP-1102087-A | — | — | None | — | — | JP | disclosed |
| US-12611415-B2 | Methods and compounds for treatment of metabolic disease | MONASH UNIVERSITY (AU) | 2026-04-28 | — | — | US | disclosed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4704905-A1 | LYMPHATIC SYSTEM-TARGETING COMPOUNDS | Sage Therapeutics, LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025080689-A1 | LIPID PRODRUGS OF BROMOLYSERGIDE AND USES THEREOF | SEAPORT THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119306780-A | Lipid prodrugs of pregnane neurosteroids and uses thereof | 海港治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12178875-B2 | Lymphatic system-directing lipid prodrugs | SEAPORT THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| JP-H01102087-A | O-(O-ETHYL-S-ALKYLPHOSPHORYL)-O-(CARBAMOYL)-PYROCATECHOL DERIVATIVE, CONTROL AGENT AGAINST PESTS CONTAINING THE SAME AND CONTROL METHOD AGAINST PESTS | BASF AG | 1989-04-19 | — | — | JP | disclosed |
| US-4788324-A | Preparation of o-(1-methoxy-2-chloro)-ethoxyphenyl N-methylcarbamate | BASF AKTIENGESELLSCHAFT (DE) | 1988-11-29 | — | — | US | disclosed |
| EP-0207913-A1 | Catechol carboxamides, process for their preparation, intermediates and a pharmaceutical preparation | Astra Läkemedel Aktiebolag (SE) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007591-A1 | CATECHOLCARBOXAMIDES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND A PHARMACEUTICAL PREPARATION | Astra Läkemedel Aktiebolag (SE) | 1986-12-31 | — | — | WO | disclosed |
| US-4537986-A | Preparation of pyrocatechol methylcarbamate | BASF AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | disclosed |
| US-3950533-A | Pyrocatechol carbamates and o-mercaptophenol carbamates and their use for combating pests | CIBA-GEIGY AG (CH) | 1976-04-13 | — | — | US | disclosed |
| US-3843720-A | PYROCATECHOL CARBAMATES AND O-MERCAPTOPHENOL CARBAMATES AND THEIR USE FOR COMBATING PESTS | CIBA GEIGY AG | 1974-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611415-B2 | Methods and compounds for treatment of metabolic disease | SUCNR1, GPR119, SLC2A1 | GAA 3266/4885MAPT 4777/4885JAK2 387/4885 |
| US-12178875-B2 | Lymphatic system-directing lipid prodrugs | LIPA, MALT1, SGMS1 | GAA 578/4885MAPT 2535/4885JAK2 1873/4885 |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | JAK1, JAK3, JAK2 | GAA 4143/4885MAPT 4085/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.